Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sanjiu Expected to Acquire Shungfeng Pharma through Auction

publication date: Dec 22, 2011
Shunfeng Pharmaceutical, China’s largest external-use drugmaker, is auctioning itself off to the highest bidder. The minimum price? An even 600 million RMB ($95 million). There is dissension between Shunfeng's minority shareholders and the company’s CEO. In addition, the company’s sales and profits are sliding lower. According to one insider, Sanjiu Medical and Pharma is the most likely to prevail in the auction. More details....

Stock Symbol: (SHE: 000999)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital